| Name | Title | Contact Details |
|---|
Exeter House is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Rooted in Relationships, Backed by Results. Our Mission is to revolutionize the perception and impact of employee well-being by creating and proving the correlation of employee well-being with bottom line revenue. To help medium and large-sized organizations by deploying and managing tailored programs that are customized for every client and personalized for each participant. To deliver total Return on Well-being for every client, including individual health improvement, heightened employee engagement, increased productivity, cultural improvement, lower healthcare costs, and higher profitability. Our Vision is to revolutionize the way corporate America values employee well-being by correlating improved employee health and employee engagement with decreased human resources costs and improved financial performance. Our Purpose is to impact our clients’ success and the quality of life of each individual we touch. Through Guaranteed Support; Guaranteed Enjoyment; Guaranteed Improvement you’ll see how we can impact your Return on Well-being (ROW) and improve the health and well-being of your workforce. Connect with us to start the change!
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.
National Genetics Institute is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. National Genetics Institute is based in Los Angeles, CA. You can find more information on National Genetics Institute at www.ngi.com
Harrington Health is a Wichita, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.